about
Immunomodulatory treatment of myelodysplastic syndromes: antithymocyte globulin, cyclosporine, and alemtuzumabExpression of PD-L1, PD-L2, PD-1 and CTLA4 in myelodysplastic syndromes is enhanced by treatment with hypomethylating agents.Peripheral blood mononuclear cell proteome changes in patients with myelodysplastic syndromeEmerging immunosuppressive drugs in myelodysplastic syndromes.CD8+ T cells drive autoimmune hematopoietic stem cell dysfunction and bone marrow failure.Autoimmune diseases and myelodysplastic syndromes.Frequent mutations in CD8 T cells from patients with pure red cell aplasia
P2860
Q26864200-9BF45AE0-58DB-4625-A718-D840E2396DC9Q33657377-172D5C4D-C507-48DB-8AD5-4653ABD7DF51Q35556586-CB030C7E-7475-4C1F-8397-C3D5F3F14673Q38060835-B4862DE6-BABB-48A1-BEFE-CB9CB421DB53Q39565006-3B4B29EF-E86A-423F-B9A4-C020177C4DDBQ40911039-48C82EF6-38A5-4908-A491-EDC091EE6C0DQ57795871-1D5209BB-83B1-4863-AEB5-7306BCC0E062
P2860
description
2010 nî lūn-bûn
@nan
2010年の論文
@ja
2010年論文
@yue
2010年論文
@zh-hant
2010年論文
@zh-hk
2010年論文
@zh-mo
2010年論文
@zh-tw
2010年论文
@wuu
2010年论文
@zh
2010年论文
@zh-cn
name
Immune dysregulation in myelodysplastic syndrome.
@ast
Immune dysregulation in myelodysplastic syndrome.
@en
type
label
Immune dysregulation in myelodysplastic syndrome.
@ast
Immune dysregulation in myelodysplastic syndrome.
@en
prefLabel
Immune dysregulation in myelodysplastic syndrome.
@ast
Immune dysregulation in myelodysplastic syndrome.
@en
P2093
P2860
P356
P1433
P1476
Immune dysregulation in myelodysplastic syndrome.
@en
P2093
Alan F List
Chiharu Sugimori
Pearlie K Epling-Burnette
P2860
P356
10.4081/HR.2010.E1
P577
2010-01-01T00:00:00Z